File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Longitudinal circulating tumor DNA (ctDNA) analysis in the phase 1b MONALEESASIA study of ribociclib (RIB) + endocrine therapy (ET) in Asian patients (pts) with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC)

TitleLongitudinal circulating tumor DNA (ctDNA) analysis in the phase 1b MONALEESASIA study of ribociclib (RIB) + endocrine therapy (ET) in Asian patients (pts) with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC)
Authors
Issue Date2021
PublisherElsevier BV. The Journal's web site is located at https://www.journals.elsevier.com/annals-of-oncology
Citation
European Society of Medical Oncology (ESMO) Congress, Virtual Meeting, Paris, France, 16-21 September 2021. Abstracts Book in Annals of Oncology, 2021, v. 32 n. Suppl. 5, p. S459-S460, no. 232P How to Cite?
AbstractBackground: The phase 1b MONALEESASIA (NCT02333370) study is assessing Asian pts with HR+/HER2– ABC treated with RIB plus ET. We report the results of a longitudinal analysis of ctDNA in this trial. Methods: MONALEESASIA included dose-escalation and -expansion phases and enrolled premenopausal and postmenopausal Japanese pts and postmenopausal Asian non-Japanese pts. In the dose-escalation phase, all pts received RIB + letrozole (LET). In the dose-expansion phase, all Asian non-Japanese pts received RIB + LET, whereas Japanese pts received RIB + LET or fulvestrant (for postmenopausal pts) or RIB + TAM + goserelin (for premenopausal pts). Cell-free DNA (cfDNA) samples were collected from pts at baseline (BL), during treatment, and at end of treatment (EOT). ctDNA was evaluated with a targeted NGS panel comprising ≈ 600 cancer-related genes. ctDNA levels were evaluated throughout treatment by best overall response (BOR). Results: 86 pts were included in this analysis, and 574 cfDNA samples were tested. Some of the most frequently altered genes were PIK3CA, TP53, and ESR1. The alteration frequency for PIK3CA and TP53 was similar from BL to EOT but was numerically higher at EOT for ESR1. There was a consistent trend of lower BL ctDNA levels in pts with partial response (PR) or stable disease (SD) vs pts with progressive disease; however, there was no difference in ctDNA levels at on-treatment time points and EOT by BOR. In all treatment arms, pts with PR and SD had a decrease in ctDNA levels at the first collected on-treatment time point vs BL. Three categories of case studies will be presented: (1) ctDNA was detectable at BL and became undetectable on treatment; (2) ctDNA increased before tumor progression; (3) ctDNA was not detectable throughout treatment. Conclusions: ctDNA levels were dynamic throughout treatment in Asian pts with HR+/HER2– ABC in MONALEESASIA. These findings suggest that on-treatment ctDNA levels may help identify pts at risk of progression.
DescriptionePoster Display - no. 232P
Persistent Identifierhttp://hdl.handle.net/10722/308475
ISSN
2020 Impact Factor: 32.976
2020 SCImago Journal Rankings: 7.954

 

DC FieldValueLanguage
dc.contributor.authorYap, YS-
dc.contributor.authorSu, F-
dc.contributor.authorJoshi, /M-
dc.contributor.authorChiu, WYJ-
dc.contributor.authorMasuda, N-
dc.contributor.authorIto, Y-
dc.contributor.authorIshikawa, T-
dc.contributor.authorAruga, T-
dc.contributor.authorKim, SJ-
dc.contributor.authorDeore, U-
dc.contributor.authorBabbar, N-
dc.contributor.authorBalbin, A-
dc.date.accessioned2021-12-01T07:53:50Z-
dc.date.available2021-12-01T07:53:50Z-
dc.date.issued2021-
dc.identifier.citationEuropean Society of Medical Oncology (ESMO) Congress, Virtual Meeting, Paris, France, 16-21 September 2021. Abstracts Book in Annals of Oncology, 2021, v. 32 n. Suppl. 5, p. S459-S460, no. 232P-
dc.identifier.issn0923-7534-
dc.identifier.urihttp://hdl.handle.net/10722/308475-
dc.descriptionePoster Display - no. 232P-
dc.description.abstractBackground: The phase 1b MONALEESASIA (NCT02333370) study is assessing Asian pts with HR+/HER2– ABC treated with RIB plus ET. We report the results of a longitudinal analysis of ctDNA in this trial. Methods: MONALEESASIA included dose-escalation and -expansion phases and enrolled premenopausal and postmenopausal Japanese pts and postmenopausal Asian non-Japanese pts. In the dose-escalation phase, all pts received RIB + letrozole (LET). In the dose-expansion phase, all Asian non-Japanese pts received RIB + LET, whereas Japanese pts received RIB + LET or fulvestrant (for postmenopausal pts) or RIB + TAM + goserelin (for premenopausal pts). Cell-free DNA (cfDNA) samples were collected from pts at baseline (BL), during treatment, and at end of treatment (EOT). ctDNA was evaluated with a targeted NGS panel comprising ≈ 600 cancer-related genes. ctDNA levels were evaluated throughout treatment by best overall response (BOR). Results: 86 pts were included in this analysis, and 574 cfDNA samples were tested. Some of the most frequently altered genes were PIK3CA, TP53, and ESR1. The alteration frequency for PIK3CA and TP53 was similar from BL to EOT but was numerically higher at EOT for ESR1. There was a consistent trend of lower BL ctDNA levels in pts with partial response (PR) or stable disease (SD) vs pts with progressive disease; however, there was no difference in ctDNA levels at on-treatment time points and EOT by BOR. In all treatment arms, pts with PR and SD had a decrease in ctDNA levels at the first collected on-treatment time point vs BL. Three categories of case studies will be presented: (1) ctDNA was detectable at BL and became undetectable on treatment; (2) ctDNA increased before tumor progression; (3) ctDNA was not detectable throughout treatment. Conclusions: ctDNA levels were dynamic throughout treatment in Asian pts with HR+/HER2– ABC in MONALEESASIA. These findings suggest that on-treatment ctDNA levels may help identify pts at risk of progression.-
dc.languageeng-
dc.publisherElsevier BV. The Journal's web site is located at https://www.journals.elsevier.com/annals-of-oncology-
dc.relation.ispartofAnnals of Oncology-
dc.relation.ispartofEuropean Society of Medical Oncology (ESMO) Congress, 2021-
dc.titleLongitudinal circulating tumor DNA (ctDNA) analysis in the phase 1b MONALEESASIA study of ribociclib (RIB) + endocrine therapy (ET) in Asian patients (pts) with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC)-
dc.typeConference_Paper-
dc.identifier.emailChiu, WYJ: jwychiu@hku.hk-
dc.identifier.authorityChiu, WYJ=rp01917-
dc.description.natureabstract-
dc.identifier.doi10.1016/j.annonc.2021.08.515-
dc.identifier.hkuros330572-
dc.identifier.volume32-
dc.identifier.issueSuppl. 5-
dc.identifier.spageS459-
dc.identifier.epageS460-
dc.publisher.placeNetherlands-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats